Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors is a research paper published in Frontiers in Oncology (2022). On theSindex it has a DataRank of 0.830. It has been cited 20 times, with 15 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.457
From this paper's citation signal
Citation Network Contribution
0.373
From 13 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 15 citers.
NCI NIH HHS
Grant: P30 CA016672
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
FWCI
1.77
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals